All posts by medical

Immunology

Global Immunology Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 – E-Industry News

The research report Immunology Market Global Industry Analysis 2019 2025 offers precise analytical information about the Immunology market. The report identifies top players in the global market and divides the market into several parameters such as major drivers market strategies and imposing growth of the key players. Worldwide Immunology Industry also offers a granular study of the market dynamics, segmentation, revenue, share forecasts and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the Immunology industry.

This Immunology market report bestows with the plentiful insights and business solutions that will support our clients to stay ahead of the competition. This market report contains categorization by companies, region, type, and application/end-use industry. The competitive analysis covered here also puts light on the various strategies used by major players of the market which range from new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and many others that leads to increase their footprints in this market. The transparent research method carried out with the right tools and methods makes this Immunology market research report top-notch.

Interesting? Apply for a sample report: http://www.intenseresearch.com/market-analysis/global-immunology-market-2018-by-manufacturers-countries-type.html#request-sample

Competitive Landscape

Global Immunology market is highly split and the major players have used numerous tactics such as new product launches, acquisitions, innovation in products, expansions, agreements, joint ventures, partnerships, and others to increase their footprints in this market.

Key players profiled in the report include: AbbVie, Amgen, F. Hoffmann-La Roche, Johnson & Johnson, Bionor Pharma, Celgene, Cellectar Biosciences, eFFECTOR Therapeutics

Market Segmentation

Immunology Market report segmentation on Major Product Type:Immuno Boosters, Immunosuppressants

Market by Application: Here, various application segments of the global Immunology market are taken into account for the research study.

Autoimmune Diseases, Oncology, Organ Transplantation, Others

Enquire Here For Queries Or Report Customization: http://www.intenseresearch.com/market-analysis/global-immunology-market-2018-by-manufacturers-countries-type.html#inquiry-for-buying

Regional Analysis

The Immunology market report keenly emphasizes on industrial affairs and developments, approaching policy alterations and opportunities within the market. The regional development methods and its predictions are explained in every key point that specifies the general performance and issues in key regions such as North America, Europe, Asia Pacific, Middle East, South America, and Middle East & Africa (MEA). Various aspects such as production capability, demand, product value, material parameters and specifications, distribution chain and provision, profit and loss, are explained comprehensively in the market report.

Key Questions Answered in Global Immunology Market Report:-

What will the market growth rate, overview, and analysis by type of global Immunology Market in 2026?

What are the key factors driving, analysis by applications and countries Global Immunology Market?

What are dynamics, this summary includes analysis of the scope and price analysis of top players profiles of Global Immunology Market?

Who are the opportunities, risk and driving forces of the global Immunology Market?

Who are the opportunities and threats faced by the vendors in the Global Immunology Market?

What are the Global Immunology market opportunities, market risk and market overview of the Market?

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia. Also, If you have any special requirements, please let us know and we will offer you the report as you want.

Here is the original post:
Global Immunology Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 - E-Industry News

Immunology

NIH clarifies meaning of ‘disadvantaged’ in bid to boost diversity in science – Science Magazine

Wonder Drake of Vanderbilt University in Nashvillein her lab with some of the students she supports through the National Institutes of Healths diversity supplements

By Jeffrey MervisDec. 13, 2019 , 4:10 PM

Wonder Drake knows how being poor can hinder someones dream of becoming a biomedical researcher.

Raised in rural Alabama by a single mother who never graduated from high school, Drake overcame those obstacles by finding mentors willing to take her under their wing. Now a professor of medicine at Vanderbilt University in Nashville, Drake has repeatedly returned that favor by participating in a National Institutes of Health (NIH) program aimed at improving the diversity of the biomedical workforce.

Under the program, NIH grantees such as Drake can win additional funding, called diversity supplements, to aid students from one of several groups underrepresented in biomedical research. Some 90% of the awards made in 2018 serve students who are Hispanic or African American, whereasfewer than 1% of investigators cite the category of economically disadvantaged when applying for a diversity supplement.

NIH officials think that tiny slice should be bigger. So last month, the agency tweaked its definition of the word disadvantaged in hopes that the diversity supplements would serve a broader swath of that population.

Diversity supplements can be used to support students from high school through postdoctoral training. NIHs previous definition of disadvantaged referred to students whose pursuit of a research career was hampered by living in an educational environment such as those found in certain rural or inner-city environments. But that language may have confused people, says Michael Lauer, who leads NIHs office of extramural research. What does [that] mean? Lauer asked in a 26 November blog announcing the change, adding that the phrase is nearly impossible to evaluate.

NIHs new definition of disadvantagedwhich applies to all of the agencys programs meant to foster diversityhas seven components. A person is eligible if they have been homeless, or qualified for a free or reduced-priced lunch in elementary or high school, or if they meet the income level requirements to receive a federal Pell grant to help finance their college education. NIH also invites in those who were in foster care, whose parents never graduated from college, or who grew up in a rural area or a region with a shortage of health professionals.

We wanted to make it easy for students to self-identify while not being overly redundant, says Jon Lorsch, director of the National Institute of General Medical Sciences in Bethesda, Maryland, the hub of NIHs diversity activities. The goal of the supplements remains the same, he says: helping students overcome barriers caused by their low economic status.

Drake, for one, applauds NIHs move. The new definition may attract more students who are immigrants, or poor Caucasians, she speculates. Just think how useful their input would be in finding solutions to the opioid crisis, which is ravaging so many low-income communities.

Drake notes that she would have met several of the new eligibility criteria when she was a student. I certainly grew up disadvantaged, she says. She is also African American, so she would have qualified in that category as well.

Drake, who has received many diversity supplements, typically chooses students from a racial or ethnic minority because its obvious. Students of color at Vanderbilt who want a research experience tend to seek her out, Drake adds.

But she also contacts nearby institutions that educate large numbers of students who fit NIHs definition of diversity. I call up the chair of the basic science department and I tell them, I need your best student, she says. Then I give them the chance to see what its like to be a scientist. The goal is to have them complete a research project over the summer, she says, and then present a poster session at a scientific conference.

The new definition of disadvantaged could help more students tap into such experiences. And Drake says, Based on my experience, the economically disadvantaged students are sometimes the most talented because they have had to overcome so much adversity.

A National Institutes of Health diversity program helped Matthew Bruce begin to trainfor a career as a biomedical researcher after he spent 4 years in prison for armed robbery.

Some diversity experts fear eligible students could shy away from identifying themselves as economically disadvantaged because of the stigma associated with the term. I was a single mother on Medicaid and food stamps during part of my student years, and also the first in my family to go to college, but I never thought of it as being a disadvantage, says a researcher who has led diversity efforts at her institution. I am also averse to playing the hardship card.

But others arent too worried. I think that students with the potential to succeed in graduate school would not be dissuaded, says Jacqueline Tanaka, a professor emeritus of biology at Temple University in Philadelphia, Pennsylvania, and former director of its Minority Access to Research Careers (MARC) program, one of NIHs longest running diversity initiatives. They are probably already carrying a lot of student debt, and this is an opportunity to get the type of research experience they need to move ahead.

In fact, Tanaka would like to see NIH broaden the definition even more to include students with backgrounds like that of Matthew Bruce, now a third-year graduate student in immunology at the University of California, Davis. In 2008, Bruce used a gun to rob a convenience store for money to support his drug habit. A few months, later he turned himself in, pleaded guilty, and served 4 years in a Pennsylvania state prison.

After his release, Bruce juggled work and a full load of courses at a local community college before transferring to Temple. There, Tanaka recruited him to the MARC program, which offers high-achieving, upper-level undergraduate students the type of research experiences they need to get into a good graduate program, the first rung on an academic career.

It may sound corny, Bruce says, but being in the MARC program was everything to me. I was feeling the imposter syndrome times 100, he says about the well-documented phenomenon of students from disadvantaged backgrounds underestimating their ability to make it in science.

I didnt come from the same background as my peers, and I hadnt really paid much attention in school [because of his drug dependency], Bruce continues. When Dr. Tanaka told me that, as a scientist, I would essentially get paid to solve problems, I said, That sounds phenomenal. Sign me up. In 2017 he graduated from Temple with a near-perfect academic record.

Bruce grew up in rural Pennsylvania, was the first in his family to attend college, and received a Pell grant, so he would likely qualify as disadvantaged under NIHs new definition. But what really sold Tanaka on Bruce was how he had overcome a huge obstacleincarcerationthat is not included in the definition.

Lorsch saysNIH is open to further revisions of the criteria for disadvantaged. Our goal is to give students as many on-ramps as possible, he says.

And money is not an impediment. Lorsch estimates that NIH could, without straining its budget, accommodate a 10-fold increase in the number of supplement applications that cite the disadvantaged category; in 2018 there were fewer than 11 such applications.

Given that NIH funds nearly two-thirds of the proposals it receives for diversity supplements, Drake doesnt understand why more of her colleagues dont apply. I think [the diversity supplements] are one of the best-kept secrets at NIH, she says. And were doing everything we can at [Vanderbilt] to spread the word.

View post:
NIH clarifies meaning of 'disadvantaged' in bid to boost diversity in science - Science Magazine

Immunology

Smallpox Was Eradicated 40 Years Ago, So Why Are the U.S. and Russia Still Holding Stocks of the Virus? – Newsweek

On 9 December, 1979, health officials declared smallpox as the first and only human disease to be eradicated in what is considered the greatest achievement of modern medicine. Four decades on, the U.S. and Russia still maintain samples of the potentially deadly virus, and the debate on whether they should be kept or destroyed rages on.

We don't know where smallpox came from. But the infectionwhich is caused by two related variola virusesis thought to date back to the Egyptian Empire in the 3rd Century BCE, with its pustules found on the head of the Egyptian Pharaoh Ramses V. Trade and the expansion of civilizations helped the disease, found only in humans, spread. Characterized by symptoms including a fever, a widespread rash of fluid-filled blisters, vomiting and diarrhea, smallpox is estimated to have killed as many as 300 million people in the 20th century alone.

Following a failed attempt to wipe out the disease in 1959, efforts were renewed in 1967. Thanks to a worldwide vaccination program, the last person to ever be naturally infected by smallpox fell ill in Somalia, on October 12, 1977. By 9 December, 1979, the WHO had concluded the virus had been eradicated worldwide. And on May 8, 1980, the 33rd World Health Assemblythrough which the World Health Organization is governed by its member statesdeclared the world free of smallpox. Amid the Cold War, the body decided it would be wise to have two smallpox repositories in the West and one in the Soviet Bloc, in the interests of political neutrality.

To this day, only two remaining stocks of the variola virus are known to exist. They are kept under high-security conditions at a U.S. Centers for Disease Control and Prevention laboratory in Atlanta, and at Russia's State Research Centre of Virology and Biotechnology (Vector) in the Siberian city of Novosibirsk. Everything known about their location is in the public domain except for the exact rooms and freezers where the samples are kept, David Relman, professor of microbiology and immunology at Stanford University, told Newsweek.

Experts agreed on keeping the virus in case the disease reappears, and in order to help to improve vaccines, create treatments, antivirals and improve diagnostics methods. Any work on variola must be pre-approved by the World Health Organization, which takes inventories on samples every year, and inspects the labs biennially.

Until these objectives are met, the World Health Organization agrees the stocks should not be destroyed. Professor Grant McFadden, director of the Biodesign Center for Immunotherapy, Vaccines, and Virotherapy at Arizona State University, told Newsweek: "There remains debate about how close each of these goals is to completion."

So far, the decision to retain the samples has been somewhat fruitful. In 2018, for instance, the FDA approved the first drug that it believes could treat smallpox. Following a meeting in September 2018, members of the WHO's Advisory Committee on Variola Virus Research were divided, but once again concluded the repositories are still needed to develop an antiviral drug different from the one approved by the FDA.

While some argue the aims of the research agenda have been essentially achieved, McFadden said, others point to the fact only one new drug is now available, the animal models to test the new vaccines are currently inadequate, and the new generation of diagnostics remain unproven, he said.

The virus is needed to test the efficacy of new vaccines and drugs, David Relman, professor of microbiology and immunology at Stanford University, told Newsweek. "And chemical synthesis of the virus, in the event of destruction and then unexpected re-emergence and the need for new testing with the virus, would take too long," he said.

But what ifothers arguethe virus was released by accident, or on purpose? As people are no longer vaccinated against smallpox, this could potentially spark a large and deadly epidemic or pandemic, Amesh A. Adalja, a senior scholar at Johns Hopkins Center for Health Security, told Newsweek. Its potential as a tool of bioterrorism adds another layer to the controversial question of smallpox stock retention.

Concerning incidents have reignited the debate over the years. Previously unknown smallpox vials were found in an FDA building at the NIH Bethesda campus back in 2014. Last year, biosecurity experts feared the publication of a study that detailed the replication of the horsepox virus could provide terrorists with a recipe for making a pathogen that causes smallpox. And in September of this year, an explosion occurred at the Vector lab, (during which the smallpox samples were unscathed).

Relman told Newsweek that while he believes it is safe, but "not foolproof," to keep the repositories, he is "much more worried about the re-synthesis of smallpox from chemicals in the library and re-booting the virus with methods that have now been published."

McFadden is also concerned by that prospect, as well as the potential existence of any undeclared stocks.

For Adalja, the time has come to get rid of smallpox once and for all. "The virus should be destroyed," he said. "As time passes, the initial reason for keeping viable virus has less support."

Read more

"In 2019, we now have achieved most of those milestones so it has become increasingly unnecessary to keep viable virus, especially since its genetic sequence is known and the virus could be recreated if needed," he argued.

"Keeping the viable stocks and working with them could lead to laboratory accidents with resultant infection and spread. The stocks could also be misused or fall into the wrong hands and be used nefariously," Adalja said.

Relman countered that in his view, the arguments for retention are stronger than the arguments for destruction. Not until re-synthesis can happen overnight and is reliable "will the balance of the arguments shift, and by then, by definition, we're back to the same or greater danger despite destruction," he said.

McFadden, meanwhile, said remains agnostic on the issue. "A great deal has been achieved on the original research goals, but the argument that more remains to be done is hard to refute," he said.

"I believe that a fully unanimous opinion of the research community and public health experts familiar with variola virus will be hard to achieve in the near future, and so the destruction decision will need to be political," he said. "It is important to have these debates about whether mankind should deliberately eliminate feared pathogens, or study them."

Follow this link:
Smallpox Was Eradicated 40 Years Ago, So Why Are the U.S. and Russia Still Holding Stocks of the Virus? - Newsweek

Immunology

Research shows how high levels of blood fat induce inflammation and organ damage – News-Medical.net

Viral and bacterial infections are not the only causes of inflammation of body tissue. It has been known for some time that certain fat molecules in our bloodstream can also trigger an inflammatory response. Patients with higher levels of these fats in their blood have a significantly greater chance of dying early from kidney damage or vascular disease. This causal link has now been clearly demonstrated by an international team of researchers led by Dr. Timo Speer of Saarland University.

The research team was able to show how these fat molecules interact with body cells and how they can mobilize the body's own immune system to damaging effect. The study's findings have now been published in the highly respected medical journal 'Nature Immunology'.

Doctors interested in ways to minimize the risk of cardiovascular disease have long had blood cholesterol levels in their sights. But other types of blood fats (also known as 'lipids') can also be damaging to health.

Our work has involved studying a special group of lipids, the triglycerides. We've been able to show that when these naturally occurring fats are present at elevated concentrations they can alter our defense cells in such a way that the body reacts as if responding to a bacterial infection. This leads to inflammation, which, if it becomes chronic, can damage the kidneys or cause atherosclerosis - the narrowing of arteries due to a build up of deposits on the inner arterial wall. And atherosclerosis is one of the main causes of heart attacks and strokes."

Timo Speer, Saarland University

Speer, who has doctorates in medicine as well as biology, is the lead author of the work just published in Nature Immunology.

The large-scale study was able to demonstrate that patients with elevated levels of triglycerides in their blood had a significantly higher mortality rate than comparison groups with a similar health history. 'Put another way, we can now say that adopting a low-fat diet can significantly extend the life expectancy of high-risk patients, such as those with diabetes or those whose blood pressure is too high,' says Timo Speer. Blood triglyceride levels rise substantially in people who eat a high-fat diet. 'As a result of biochemical changes, the triglycerides develop toxic properties that activate the body's innate immune system. This initiates a series of self-destructive processes including those in which the walls of the arteries are attacked and the blood vessels become occluded, reducing blood flow,' explains Speer. The study has established a definitive link between the chronic inflammation triggered by an elevated triglyceride concentration in the blood and secondary diseases such as kidney failure or heart attack. 'We hope that our results will help in developing new strategies for treating and preventing these life-threatening diseases,' says Timo Speer.

The publication in Nature Immunology is one of the results of the diverse range of scientific investigations being carried out as part of a Transregional Collaborative Research Centre between Saarland University and RWTH Aachen University. The focus of the work performed within the Collaborative Research Centre is to discover which cardiac and vascular diseases can be caused by chronic kidney disease. The German Research Foundation (DFG) is funding this major research programme with ten million euros over a three-year period. Timo Speer is the lead researcher for one the research projects. He is also a senior physician at Saarland University Hospital and laboratory director for experimental and translational nephrology.

Source:

Journal reference:

Zewinger, S., et al. (2019) Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nature Immunology. doi.org/10.1038/s41590-019-0548-1.

Posted in: Medical Science News | Medical Research News | Medical Condition News

Tags: Apolipoprotein, Atherosclerosis, Blood, Blood Pressure, Blood Vessels, Cardiovascular Disease, Cholesterol, Chronic Kidney Disease, Diabetes, Diet, Heart, Heart Attack, Hospital, Immune System, Immunology, Inflammasome, Inflammation, Kidney, Kidney Disease, Kidney Failure, Laboratory, Life Expectancy, Lipids, Medicine, Mortality, Nephrology, Research, Triglyceride, Vascular

View original post here:
Research shows how high levels of blood fat induce inflammation and organ damage - News-Medical.net

Immunology

BRIEFEquillium and Biocon expand itolizumab deal – The Pharma Letter

La Jolla, California-based immunology specialist Equillium has inked a deal with Biocon, expanding an existing collaboration and license agreement.

The deal builds on the firms research into Biocons novel biologic itolizumab, granting Equillium exclusive rights for developing and commercializing the candidate in Australia and New Zealand. The firm secured rights to the US and Canadian markets in May 2017.

Itolizumab is a novel first-in-class humanized anti-CD6 monoclonal antibody, which Biocon developed and launched in India under the brand name Alzumab, to treat moderate to severe plaque psoriasis in 2013.

The firms are working to develop the candidate for a wide range of autoimmune disorders.

More here:
BRIEFEquillium and Biocon expand itolizumab deal - The Pharma Letter

Genetics

A New Genetic Based Dating App Will Soon Arrive in The Market – Science Market News

Harvard biologist George Church already needed to apologize for a palling around with Jeffrey Epstein even after the financier pleaded to responsible for preying on minors a decade in the past. Now hes elevating eyebrows once morewith plans for a genetics-based courting app.

In an interview with 60 Minutes, Church stated his expertise would pair people based on the propensity of their genes, when mixed in kids, to remove hereditary ailments. Yuko, in contrast, the app, as described, to the Nazi purpose of cultivating a grasp race: I believed we realized after World War II that we werent going to be doing that, she stated.

The church was a part of the coterie of scientists with whom Epstein ingratiated himself via large donations, and Epstein helped bankroll his lab from 2005 to 2007. Church has admitted he repeatedly met and spoke with Epstein for years after the 2008 plea deal that landed him on the intercourse-offender registry.

Epstein had a twisted take on genetics, internet hosting scientific conferences at which he expressed his want to propagate his personal genome by impregnating as much as 20 girls at a time at his New Mexico ranch, like cattle inventory.

Within the 60 Minutes interview, Church referred to as his ties to Epstein unlucky and added: You do not all the time know your donors in addition to you want to.

However, a lot of the phase was dedicated to Churchs genetic-engineering work at Harvard Medical School, together with the app that might theoretically display out potential mates with the improper DNA.

The geneticist didnt drop the apps to identify, or how far alongside its in improvement. He additionally didnt reply to a request for a remark.

Within the interview, the Church acknowledged the drawbacks of genetic sorting. He suffers from dyslexia, consideration deficit dysfunction, and narcolepsyissues that may render him an incompatible match to many. Yuko stated the choice standards could be a sticking level for Churchs app thought.

More here:
A New Genetic Based Dating App Will Soon Arrive in The Market - Science Market News

Genetics

The many ancestral genetic lines of India – Hyderus Cyf

The first study resulting from the GenomeAsia 100K project has revealed that Asia has at least ten distinct genetic ancestral lines, compared to the single genetic lineage found in northern Europe.

The results were found from the genomic sequencing of 598 individuals belonging to 55 ethnic groups from India. The project is set to expand to cover the genomes of 100,000 individuals across southeast Asia.

To put it into context, imagine we looked at all people of European descent and based on the level of their genetic diversity, observed that they could all be grouped into just one ancestral lineage or population, said Stephan C. Schuster, professor at Nanyang Technological University in Singapore.

Now, if we took that same approach with our new data from people of Asian descent, then based on the much higher levels of genetic diversity observed we would say that there are ten different ancestral groups or lineages in Asia.

India has long been underrepresented in global genetic databanks. India represents almost twenty percent of the worlds population and is on track to become the worlds most populous nation in the coming decades. Despite this, only 0.2 percent of fully mapped genomes in global databanks are of Indian origin.

In adding genetic diversity to the global databanks, the GenomeAsia project, therefore, is vital as it allows for the analysis of diseases and conditions linked to a genetic origin that is unique among the ethnic groups present in Asia.

Despite low coverage in global databanks, current information on Indian genetics has identified six genes that are unique among the Indian population. These genes all present unique risk factors in the development of diabetes. To an extent, this explains part of the increase in prevalence of diabetes within India, with the unique genetic risk factors combining with increasingly unhealthy lifestyles to rapidly increase the rates of diabetes.

We have a great opportunity to apply genomics in India to understand, manage and treat diseases. Genomic analysis of our unique population groups and disease cohorts will lead to identification of genetic mutations and drug targets not just for India but for the whole world, said Sam Santhosh, chief executive officer of genomics-driven research and diagnostics company MedGenome and one of the study authors.

This is a position also held by the Indian government, with increased investment into genome sequencing sourced from the Centre. The potential benefits to the healthcare system are both considerable and multifaceted. Knowledge of unique risks among Indias population can allow for considerable improvements to preventative healthcare, as well as drug targeting in order to make use of the most effective drugs for the individual.

Like Loading...

Related

More:
The many ancestral genetic lines of India - Hyderus Cyf

Genetics

Penn Team Finds Genetic Variant Largely Found in Patients of African Descent that Increases Heart Failure Risk – Clinical OMICs News

A genetic variant found in about 3% of people of African ancestry is a more significant cause of heart failure than previously believed, according to a multi-institution study led by researchers at Penn Medicine. The researchers also found that this type of heart failure is underdiagnosed. According to their study, 44% of TTR V122Ivariant carriers older than age 50 had heart failure, but only 11% of these individuals had been diagnosed with hATTR-CM. The average time to diagnosis was three years, indicating both high rates of underdiagnoses and prolonged time to appropriate diagnosis

This study suggests that workup for amyloid cardiomyopathy and genetic testing of TTR should be considered, when appropriate, to identify patients at risk for the disease and intervene before they develop more severe symptoms or heart failure, said the studys lead author Scott Damrauer, M.D., an assistant professor of Surgery at Penn Medicine and a vascular surgeon at the Corporal Michael J. Crescenz VA Medical Center. (Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania and the University of Pennsylvania Health System.)

In this study, researchers from Penn Medicine and the Icahn School of Medicine at Mount Sinai used a genome-first approach, performing DNA sequencing of 9,694 individuals of African and Latino ancestry enrolled in either the Penn Medicine BioBank (PMBB) or the Icahn School of Medicine at Mount Sinai BioMe biobank (BioMe). Researchers identified TTR V122I carriers and then examined longitudinal electronic health record-linked genetic data to determine which of the carriers had evidence of heart failure.

The findings, which were published today in JAMA, are particularly important given the US Food and Drug Administrations (FDA) approval of the first therapy (tafamidis) for ATTR-CM in May 2019. Prior to tafamidiss approval, treatment was largely limited to supportive care for heart failure symptoms and, in rare cases, heart transplant.

Our findings suggest that hATTR-CM is a more common cause of heart failure than its perceived to be, and that physicians are not sufficiently considering the diagnosis in certain patients who present with heart failure, said the studys corresponding author Daniel J. Rader, M.D., chair of the Department of Genetics at Penn Medicine. With the recent advances in treatment, its critical to identify patients at risk for the disease and, when appropriate, perform the necessary testing to produce an earlier diagnosis and make the effective therapy available.

hATTR-CM, also known as cardiac amyloidosis, typically manifests in older patients and is caused by the buildup of abnormal deposits of a specific transthyretin protein known as amyloid in the walls of the heart. The heart walls become stiff, resulting in the inability of the left ventricle to properly relax and adequately pump blood out of the heart. However, this type of heart failurewhich presents similar to hypertensive heart disease is common, and the diagnosis of hATTR-CM is often not considered.

Tafamidis meglumine is a non-NSAID benzoxazole derivative that binds to TTR with high affinity and selectivity. TTR acts by transporting the retinol-binding protein-vitamin A complex. It is also a minor transporter of thyroxine in blood. Its tetrameric structure can become amyloidogenic by undergoing rate-limiting dissociation and monomer misfolding.

Continue reading here:
Penn Team Finds Genetic Variant Largely Found in Patients of African Descent that Increases Heart Failure Risk - Clinical OMICs News

Genetics

Were Living In The DNA Future, But Its Not The One We Were Promised – BuzzFeed News

Ariel Davis for BuzzFeed NewsShare on Facebook Share on Facebook Share on Pinterest Share on Pinterest Pinterest Pinterest

Genetics just got personal. So boasted the website of 23andMe in 2008, just after launching its DNA testing service.

As we entered this decade, a small cohort of companies 23andMe, its Silicon Valley neighbor Navigenics, and Icelandic competitor deCODE Genetics were selling a future of personalized medicine: Patients would hold the keys to longer and healthier lives by understanding the risks written into their DNA and working with their doctors to reduce them.

We all carry this information, and if we bring it together and democratize it, we could really change health care, 23andMe cofounder Anne Wojcicki told Time magazine when it dubbed the companys DNA test 2008s invention of the year, beating out Elon Musks Tesla Roadster.

But in reality, the 2010s would be when genetics got social. As the decade comes to a close, few of us have discussed our genes with our doctors, but millions of us have uploaded our DNA profiles to online databases to fill in the details of our family trees, explore our ethnic roots, and find people who share overlapping sequences of DNA.

Advertisement

Its become like Facebook for genes, driven by the same fundamental human desire to connect. And, as with Mark Zuckerbergs social media behemoth, this is the decade we reckoned with what it really means to hand over some of our most personal data in the process.

A 23andMe saliva collection kit for DNA testing.

It all panned out differently from the way I imagined in 2009, when I paid $985 to deCODE and $399 to 23andMe to put my DNA into the service of science journalism. (I spared my then-employer, New Scientist magazine, the $2,500 charge for the boutique service offered by Navigenics.)

I was intrigued by the potential of DNA testing for personalized medicine, but from the beginning, I was also concerned about privacy. I imagined a future in which people could steal our medical secrets by testing the DNA we leave lying around on discarded tissues and coffee cups. In 2009, a colleague and I showed that all it took to hack my genome in this way was a credit card, a private email account, a mailing address, and DNA testing companies willing to do business without asking questions.

Advertisement

Much of the rest of what I wrote about DNA testing back then reflected pushback from leading geneticists who argued that the companies visions of personalized medicine werent ready for primetime.

As I explored the reports offered by 23andMe and deCODE, I couldnt help but agree especially when deCODE wrongly concluded that I carry two copies of a variant of a gene that would give me a 40% lifetime chance of developing Alzheimers. (Luckily, it wasnt cause for panic. Id pored over my DNA in enough detail by then to know that I carry only one copy, giving me a still-elevated but much less scary lifetime risk of about 13%.)

Despite such glitches, it still seemed that medicine was where the payoffs of mainstream genetic testing were going to be. As costs to sequence the entire genome plummeted, I expected gene-testing firms to switch from using gene chips that scan hundreds of thousands of genetic markers to new sequencing technology that would allow them to record all 3 billion letters of our DNA.

So in 2012, eager to provide our readers with a preview of what was to come, New Scientist paid $999 for me to have my exome sequenced in a pilot project offered by 23andMe. This is the 1.5% of the genome that is read to make proteins and is where the variants that affect our health are most likely to lurk.

Experts at the Medical College of Wisconsin in Milwaukee analyzed my exome. While they werent at that point able to tell me much of medical significance that I didnt already know, the article I wrote from the experience in 2013 predicted a future in which doctors would routinely scour their patients genomes for potential health problems and prescribe drugs that have been specifically designed to correct the biochemical pathways concerned.

Advertisement

Im glad I included an important caveat: This may take several decades.

By then, the revolution promised by 23andMe and its competitors was faltering. Navigenics and deCODE had both been acquired by bigger companies and stopped selling DNA tests directly to the public.

23andMe, backed by the deep pockets of Google and other Silicon Valley investors, had enough cash to continue. But it fell foul of the FDA, which had decided that the company was selling medical devices that needed official approval to be put on the market. In a 2013 warning letter, the FDA said that 23andMe had failed to provide adequate evidence that its tests produced accurate results. By the end of 2013, 23andMe had stopped offering assessments of health risks to new customers.

Since then, the company has slowly clawed its way back into the business of health. In 2015, it was given FDA approval to tell customers whether they were carriers for a number of inherited diseases; in 2017, it started providing new customers with assessments of health risks once more.

I recently updated my 23andMe account, getting tested on the latest version of its chip. My results included reports on my genetic risk of experiencing 13 medical conditions. Back in 2013, there were more than 100 such reports, plus assessments of my likely responses to a couple dozen drugs.

In the lab, discovery has continued at a pace, but relatively few findings have found their way into the clinic.

Advertisement

If youve recently been pregnant, you were probably offered blood tests to tell whether your fetus had a serious genetic abnormality. And if youve been diagnosed with cancer, a biopsy may have been sequenced to look for mutations that make some drugs a good bet and other ones a bust. Neither would have been common a decade ago.

But the wider health care revolution envisaged by Wojcicki remains far off.

A few weeks ago, I saw my doctor to discuss my moderately high blood cholesterol and had a conversation that Id once predicted would be common by now. I had signed up for a project called MyGeneRank, which took my 23andMe data and calculated my genetic risk of experiencing coronary artery disease based on 57 genetic markers, identified in a 2015 study involving more than 180,000 people.

My genetic risk turns out to be fairly low. After I pulled out my phone and showed my doctor the app detailing my results, we decided to hold off on taking a statin for now, while I make an effort to improve my diet and exercise more. But it was clear from her reaction that patients dont usually show up wanting to talk about their DNA.

We have all these naysayers and an immense body of research that is not being used to help patients, said Eric Topol, director of the Scripps Research Translational Institute in La Jolla, California, which runs the MyGeneRank project.

Advertisement

Joseph James DeAngelo, the suspected "Golden State Killer," appears in court for his arraignment in Sacramento, April 27, 2018.

23andMes collision with the FDA wound up being a turning point in ways I didnt anticipate at the time. From the start, the company included an assessment of customers ancestries as part of the package. But after the FDA cracked down, it pivoted to make ancestry and finding genetic relatives its main focus. Offering the test at just $99, 23andMe went on a marketing blitz to expand its customer base competing with a new rival.

Ancestry.com launched its genome-scanning service in May 2012 and has since gone head-to-head with 23andMe through dueling TV ads and Black Friday discount deals.

DNA tests became an affordable stocking filler, as millions of customers were sold a journey of self-discovery and human connection. We were introduced to new genetic relatives. And we were told that the results might make us want to trade in our lederhosen for a kilt or connect us to distant African ancestors.

Today, Ancestrys database contains some 15 million DNA profiles; 23andMes more than 10 million. Family Tree DNA and MyHeritage, the two other main players, have about 3.5 million DNA profiles between them. And for the most dedicated family history enthusiasts, there is GEDmatch, where customers can upload DNA profiles from any of the main testing companies and look for potential relatives. It contains about 1.2 million DNA profiles.

Advertisement

So far, so much fun. But DNA testing can reveal uncomfortable truths, too. Families have been torn apart by the discovery that the man they call Dad is not the biological father of his children. Home DNA tests can also be used to show that a relative is a rapist or a killer.

That possibility burst into the public consciousness in April 2018, with the arrest of Joseph James DeAngelo, alleged to be the Golden State Killer responsible for at least 13 killings and more than 50 rapes in the 1970s and 1980s. DeAngelo was finally tracked down after DNA left at the scene of a 1980 double murder was matched to people in GEDmatch who were the killer's third or fourth cousins. Through months of painstaking work, investigators working with the genealogist Barbara Rae-Venter built family trees that converged on DeAngelo.

Genealogists had long realized that databases like GEDmatch could be used in this way, but had been wary of working with law enforcement fearing that DNA test customers would object to the idea of cops searching their DNA profiles and rummaging around in their family trees.

But the Golden State Killers crimes were so heinous that the anticipated backlash initially failed to materialize. Indeed, a May 2018 survey of more than 1,500 US adults found that 80% backed police using public genealogy databases to solve violent crimes.

Advertisement

I was very surprised with the Golden State Killer case how positive the reaction was across the board, CeCe Moore, a genealogist known for her appearances on TV, told BuzzFeed News a couple of months after DeAngelos arrest.

The new science of forensic genetic genealogy quickly became a burgeoning business, as a company in Virginia called Parabon NanoLabs, which already had access to more than 100 crime scene samples through its efforts to produce facial reconstructions from DNA, teamed up with Moore to work cold cases through genealogy.

Before long, Parabon and Moore were identifying suspected killers and rapists at the rate of about one a week. Intrigued, my editor and I decided to see how easy it would be to identify 10 BuzzFeed employees from their DNA profiles, mimicking Parabons methods. In the end, I found four through matches to their relatives DNA profiles and another two thanks to their distinctive ancestry. It was clear that genetic genealogy was already a powerful investigative tool and would only get more so as DNA databases continued to grow.

A backlash did come, however, after two developments revealed by BuzzFeed News in 2019. In January, Family Tree DNA disclosed that it had allowed the FBI to search its database for partial matches to crime-scene samples since the previous fall without telling its customers. I feel they have violated my trust, Leah Larkin, a genetic genealogist based in Livermore, California, told BuzzFeed News at the time.

Then, in May, BuzzFeed News reported that police in Centerville, Utah, had convinced Curtis Rogers, a retired Florida businessperson who cofounded GEDmatch, to breach the sites own terms and conditions, which were supposed to restrict law enforcement use to investigations of homicides or sexual assaults. That allowed Parabon to use matches in the database to identify the perpetrator of a violent assault.

Advertisement

Larkin and other genealogists condemned the move, calling it the start of a slippery slope that would see the method being used to investigate more trivial crimes.

As barbs flew between genealogists working with law enforcement and those who advocate for genetic privacy, GEDmatch responded with new terms of service that extended the definition of violent crime, but also required users to explicitly opt in for their DNA profiles to be included in law enforcement searches.

Overnight, GEDmatch became useless for criminal investigations. Since then, the number of users opting in for matching to crime-scene samples has slowly increased, and now stands at more than 200,000. But progress in cracking criminal cases has remained slow.

Now that cops have seen the power of forensic genetic genealogy, however, they dont want to let it go. In November, the New York Times revealed that a detective in Florida had obtained a warrant to search the entirety of GEDmatch, regardless of opt-ins. It seems only a matter of time before someone tries to serve a warrant to search the huge databases of 23andMe or Ancestry, which dont give cops access sparking legal battles that could go all the way to the Supreme Court.

Genetic privacy, barely mentioned as millions of us signed up to connect with family across the world and dig into our ancestral roots, is suddenly front and center.

This week, Rogers and the other cofounder of GEDmatch, John Olson, removed themselves from the heat when they sold GEDmatch to Verogen, a company in San Diego that makes equipment to sequence crime-scene DNA. Verogen CEO Brett Williams told BuzzFeed News that he sees a business opportunity in charging police for access to the database but promised to respect users privacy. Were not going to force people to opt in, he said.

Advertisement

But it isnt just whether cops can run searches against your DNA. 23andMe may not share your information with law enforcement, but customers are asked when they signed up whether if they are OK with their de-identified DNA being used for genetic research.

It might not be obvious when you fill in the consent form, but this lies at the heart of 23andMes business model. The reason the company pushed so hard to expand its database of DNA profiles is to use this data in research to develop new drugs, either by itself or by striking deals with pharmaceutical companies.

Ancestry has also asked its users to consent to participate in research, teaming up with partners that have included Calico, a Google spinoff researching ways to extend human lifespan.

You might be comfortable with all of this. You might not. You should definitely think about it because when the information is your own DNA, there really is no such thing as de-identified data.

That DNA profile is inextricably tied to your identity. It might be stripped of your name and decoupled from the credit card you used to pay for the test. But as 23andMe warns in its privacy policy: In the event of a data breach it is possible that your data could be associated with your identity, which could be used against your interests.

Advertisement

And because you share a large part of your genome with close relatives, when you put your DNA profile into a companys database, you arent only making a decision for yourself: Their privacy is on the line, too.

Whether its due to concerns about privacy, a saturated market, or just that the novelty has worn off, sales of DNA ancestry tests are slowing. Ancestry has responded by offering a new product focused on health risks. Unlike 23andMe, it requires that tests are ordered through PWNHealth, a national network of doctors and genetic counselors.

Will this be the development that takes us back to the future I once imagined? Maybe so, but if the roller coaster of the past decade has taught me anything, its to be wary about making any predictions about our genetic future.

Peter Aldhous is a Science Reporter for BuzzFeed News and is based in San Francisco.

Contact Peter Aldhous at peter.aldhous@buzzfeed.com.

Got a confidential tip? Submit it here.

Excerpt from:
Were Living In The DNA Future, But Its Not The One We Were Promised - BuzzFeed News

Genetics

DNA Genetics Announces Agreement With Green Peak To Make The Most Of Michigan Adult-Use Cannabis Market – Benzinga

OG DNA Genetics recently disclosed a licensing agreement in conjunction with Green Peak Innovations, a medical cannabis producer and distributor in the Michigan market.

This arrangement will concede Green Peak Innovations consent to the DNA brand and access to their genetics portfolio for use at the companys cannabis cultivation and processing plant in Harvest Park, Michigan. Additionally to growing DNA genetics, Green Peak has entered the retail sector, with several locations around the state.

The recent permit of adult-use cannabis police in Michigan will enable Green Peak to supply recreational and medical users high-quality strains.

Want to hear exclusive updates on the adult-use licensing process? Check out the next meetup with MRA Executive Director, Andrew Brisbo on Dec. 18 at the Benzinga Headquarters! Get your tickets here before they sell out!

"By partnering with Green Peak Innovations, we position ourselves to expand into the rapidly developing Michigan cannabis market alongside a proven and trusted cannabis producer and distributor," said Charles Phillips, CEO of DNA Genetics.

Jeff Radway, CEO of Green Peak Innovations said, "We appreciate what DNA has accomplished for the cannabis industry and are excited to partner with them. We believe that by incorporating DNAs library of best-in-class cultivars and award-winning genetics into our facility, we can further enhance our ability to deliver the highest-quality products to Michigan and eventually the entire United States."

2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Follow this link:
DNA Genetics Announces Agreement With Green Peak To Make The Most Of Michigan Adult-Use Cannabis Market - Benzinga